• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OPKO Health Inc. (Amendment)

    2/9/23 11:27:47 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    SC 13G/A 1 tv01588-opkohealthinc.htm SCHEDULE 13G/A opkohealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  OPKO Health Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  68375N103

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  68375N103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    321,219

    7.  SOLE DISPOSITIVE POWER

    40,364,167

    8.  SHARED DISPOSITIVE POWER

    756,327

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    41,120,494

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.32%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    OPKO Health Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    4400 Biscayne Boulevard
    Miami, FL 33137

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    68375N103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $OPK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    SEC Filings

    See more
    • SEC Form 10-Q filed by OPKO Health Inc.

      10-Q - OPKO HEALTH, INC. (0000944809) (Filer)

      5/1/25 4:04:56 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      4/30/25 4:07:22 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OPKO HEALTH, INC. (0000944809) (Filer)

      4/23/25 4:09:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/10/25 5:07:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/8/25 5:34:21 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $164,850 worth of shares (100,000 units at $1.65) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/1/25 5:21:45 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Financials

    Live finance-specific insights

    See more
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

      MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participan

      4/17/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

      MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX's ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggere

      2/27/25 4:10:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

      SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/15/24 4:39:33 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OPKO Health Inc.

      SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

      11/13/24 4:30:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

      SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/12/24 4:54:06 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Krasno Richard M

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/23/25 5:21:30 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lachman Prem A

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/23/25 5:19:09 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Medel Roger Md

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/23/25 5:16:10 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

      MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participan

      4/17/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

      The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities for Future US-Produced Products Including its Florida Sunshine Brand of Vitamins and Supplements Due to Tariff Impact COCONUT GROVE, Fla., April 11, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global e-Commerce provider, today provided an update on the impact of current United States/China tariffs on its e-Commerce development program as a result of China's escalation in tariffs placed on US-produced goods imported into the country. This condition is expected to have a material impact on anticipated sales of US products into China.

      4/11/25 4:05:00 PM ET
      $NXPL
      $OPK
      Telecommunications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Opko Health

      Analyst initiated coverage of Opko Health with a rating of Neutral

      4/25/25 8:32:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opko Health upgraded by Barrington Research with a new price target

      Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

      6/29/23 9:11:26 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Opko Health with a new price target

      H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

      12/15/22 8:08:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OPK
    Leadership Updates

    Live Leadership Updates

    See more
    • OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

      WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

      9/23/24 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

      NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

      9/15/22 4:05:00 PM ET
      $OPK
      $TALK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services
    • OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

      MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

      6/22/21 8:00:00 AM ET
      $OPK
      $NVTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities